Zentalis Q2 cash $426.4M; FDA partial hold on azenosertib; CMO resigns

Zentalis Pharmaceuticals, Inc.

2024-Q2 EPS reported -$1.10 revenue$40,560,000

Cash, equivalents and marketable securities $426.4M as of June 30; R&D expense $48.4M (Q2 2024); cash runway into mid-2026.
FDA placed partial clinical hold on azenosertib June 18 after two deaths in DENALI study; resolution timelines uncertain.
Discontinued development of BCL-2 inhibitor ZN-d5; combination with azenosertib in AML phase 1 stopped.
CMO Diana Hausman stepped down effective Aug 8; CEO Kimberly Blackwell appointed Interim CMO; replacement search ongoing.
Expected 2H milestones: DENALI Cohort 1b topline, azenosertib Phase 1b final results, MAMMOTH data with GSK, others.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.